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Pimecrolimus Inhibits the Elicitation Phase but Does Not
Suppress the Sensitization Phase in Murine Contact Hypersensitivity,
in Contrast to Tacrolimus and Cyclosporine A1
Josef G. Meingassner, Hermann Fahrngruber, and Assadollah Bavandi
Novartis Research Institute,Vienna, Austria
Pimecrolimus (SDZ ASM 981, Elidel) is a nonsteroid
in£ammatory cytokine inhibitor speci¢cally developed
for the treatment of in£ammatory skin diseases. Its ef-
fect on the elicitation and sensitization phases of oxazo-
lone-induced contact hypersensitivity was compared
with tacrolimus and cyclosporine A (CyA) in BALB/c
mice using the ear swelling assay. The compounds were
administered orally. Elicitation was dose-dependently
inhibited by all three compounds. The minimal e¡ec-
tive doses were 30 mg per kg (pimecrolimus, tacroli-
mus) and 90 mg per kg (CyA), respectively. There was
no impairment of sensitization by pimecrolimus up to
the highest dose tested (120 mg per kg), in contrast to
CyA (60% inhibition at 60 mg per kg) and tacrolimus
(71% inhibition at 30 mg per kg).Weight and cellularity
of the draining lymph nodes in mice treated with ta-
crolimus or CyA during sensitization were reduced. In
addition, proliferation of T cells after secondary stimu-
lation was inhibited in cell cultures from lymph nodes
of mice treated with tacrolimus or CyA. Thus, in
contrast to tacrolimus and CyA, pimecrolimus exerts
a more selective immunomodulatory e¡ect. It does
not impair the primary immune response (sensitiza-
tion phase) but e¡ectively inhibits the secondary phase,
the elicitation phase that is the clinical manifestation
of contact hypersensitivity. Key words: allergic contact der-
matitis/cyclosporine A/DNBS/DNFB/elicitation phase/mouse/
oxazolone/pimecrolimus/sensitization phase/tacrolimus. J Invest
Dermatol 121:77 ^80, 2003
T
he ascomycin macrolactam derivative pimecrolimus
(SDZ ASM 981, Elidel) is a nonsteroid in£ammatory
cytokine inhibitor speci¢cally developed for the
treatment of in£ammatory skin diseases. Clinical stu-
dies in more than 4000 patients with atopic dermati-
tis have proved topical pimecrolimus to be highly e⁄cacious and
safe in adults, children, and infants as young as 3 mo (Harper et al,
2001; Luger et al, 2001; Eichen¢eld et al, 2002; Kapp et al, 2002;
Van Leent et al, 2002;Wahn et al, 2002). A phase I/II 4 wk study
in patients with psoriasis revealed oral pimecrolimus to be highly
e⁄cacious and well tolerated (Rappersberger et al, 2002). The
therapeutic potential of this compound for skin diseases has been
identi¢ed in laboratory animals with experimentally induced
contact hypersensitivity (allergic contact dermatitis, ACD), used
as a model of Langerhans-cell-dependent T-lymphocyte-media-
ted skin in£ammations (Meingassner et al, 1997). Inhibition of
the elicitation phase of ACD has been used as a pharmacody-
namic parameter to pro¢le topical and oral pimecrolimus in
mice, rats, and domestic pigs.
ACD develops in two phases, the clinically silent sensitization
phase and the clinically apparent elicitation phase, which is the
physically disturbing in£ammatory phase. The sensitization phase
is initiated by the epicutaneous exposure to a hapten and is char-
acterized by antigen processing and presentation by Langerhans
cells and a consecutive priming of hapten-speci¢c T cells in the
draining lymph node. In the elicitation phase, upon repeated con-
tact with the sensitizer local release of in£ammatory mediators
modulates the skin microenvironment, which facilitates extrava-
sation of in£ammatory leukocytes and hapten-speci¢cT lympho-
cytes amplifying a background in£ammatory response to the
hapten into a more vigorous hapten-speci¢c process (Grabbe et al,
1996; Grabbe and Schwarz, 1998; Tsuji et al, 2000)
The objective of this study was to investigate whether pime-
crolimus has also an e¡ect on the sensitization phase and to com-
pare the activity of pimecrolimus, tacrolimus, and cyclosporine A
(CyA) at equal oral doses on both the elicitation and sensitization
phases in the same experimental setting. Both comparators
are also calcineurin inhibitors and, although originally developed
as immunosuppressants for the prevention of allograft rejection,
are now used in dermatology, either topically as Protopic
(tacrolimus) or orally as Neoral (CyA), against in£ammatory skin
diseases (Koo, 1995; Ruzicka et al, 1999; Bornh˛vd et al, 2001).
MATERIALS ANDMETHODS
Test compounds Pimecrolimus (SDZ ASM 981) was synthesized at
Novartis Pharma, Basle, Switzerland, and prepared as a 20% solid
solution. Tacrolimus (FK 506, Prograf) and CyA (Neoral) were used as
marketed products, purchased from a local pharmacy. The ¢nal doses
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were adjusted by dilutions with the required amount of liquid dosing
medium (vehicle) under continuous stirring immediately before use. The
doses, expressed as weight of test substance (mg) per weight (kg) of test
animals, were applied in volumes of 10 ml per kg body weight.
Laboratory animals Ten-week-old to 12-wk-old female BALB/
cAnNCrl mice were used. The animals were supplied by Charles River,
Sulzfeld, Germany, and maintained conventionally under standardized
conditions (22711C, 55%75% relative humidity, 10 changes of fresh air,
per hour 12 h day/12 h night cycle) in Makrolon cages with sawdust
bedding. Standard laboratory chow (SNIFF R/M-H diet for mice and
rats, Soest, Germany) and drinking water was given ad libitum. In each
experiment groups of six to 16 mice were used after an acclimatization
period of 8^10 d. Two days before the principal investigations the animals
were transferred groupwise from the stock housing to the experimental
housing in type III cages (up to 10 mice per cage).
The animals were used according to an approved protocol under the license
MA 4009/99 (Magistratsabteilung No. 58, Amt derWiener Landesregierung).
Test on elicitation phase In three separate studies groups of eight mice
each were sensitized on the shaved abdomen with 50 ml of oxazolone
(Sigma-Aldrich, St. Louis, MO; 2% in acetone) on day 1 and challenged
with 10 ml 0.5% oxazolone on the inner surface of the right ear. The
unchallenged left ears served as normal controls and contact
hypersensitivity reaction was evaluated from the di¡erence in auricular
weights (as a measure of in£ammatory swelling) 24 h after the challenge
when the response peaks. The test animals were treated twice orally (2 h
before and 4 h after the challenge) with pimecrolimus, tacrolimus, or
CyA at dose levels of 10, 30, and 90 mg per kg. Control animals were
treated with the vehicle only.
Test on sensitization phase Groups of eight or 16 animals were
sensitized with oxazolone on day 1 as described above and treated orally
with the test compounds 2 h before and 4, 24, and 48 h after the exposure
to oxazolone. Pimecrolimus was administered at 30, 90, and 120 mg per kg,
tacrolimus at 10 and 30 mg per kg, and CyA at 30 and 60 mg per kg.
Control animals were treated with the vehicles alone. Two days after the
last treatment (day 5) the animals were sacri¢ced and the draining lymph
nodes were excised, weighed, and collected in RPMI 1640 medium
(GibcoBRL, Paisley, UK) supplemented with 10% heat-inactivated fetal
bovine serum, 100 IU penicillin per ml, 100 mg streptomycin per ml, 2
mM L-glutamine, 1 mM sodium pyruvate, 50 mM 2-mercaptoethanol,
and 1% minimum of nonessential amino acids (GibcoBRL). Lymph node
cell suspensions were prepared by gently pressing the mechanically
disrupted tissue through a sterile nylon sieve (cell strainer, 70 mm, Becton
Dickenson-Falcon, Le Pont De Claix, France). The cells were washed and
resuspended in RPMI medium, and cells 5^20 mm in size were counted
electronically (CASY 1 TT, Schr£e System, Reutlingen, Germany). Cell
viability was analyzed with a £ow cytometer (FACSCalibur £ow
cytometer) and accompanying Cell Quest software (Becton Dickenson,
San Jose, CA) after staining with 7-aminoactinomycin D (7-AAD, BD-
Pharmingen, Los Angeles, CA). (The ratio of nonviable 7-AAD-positive
cells was similar in all inocula (3%^4.5%).) Aliquots were used to inject
naive recipient animals intravenously with 5107 primed lymph node
cells (Salerno et al, 1998). Immediately after the cell transfer, the recipients
(eight per dose group) were challenged with oxazolone on the ears and
evaluated for hypersensitivity response 24 h later as described in the
previous section. Three independent studies were performed.
(Adoptive transfer experiments have been preferred to challenge studies
in actively sensitized and treated mice in order to exclude inhibition of the
elicitation phase by possible drug residuals from treatment performed at
the sensitization period a short time before.)
Test on hapten-speci¢c Tcell proliferation In three studies groups of
eight mice were sensitized on the shaved abdomen with 50 ml 0.5% 2,4-
dinitro£uorobenzene (DNFB, Sigma-Aldrich, in acetone:olive oil, 4:1
vol/vol) on day 1 and treated orally with 90 mg per kg pimecrolimus,
10 mg per kg tacrolimus, 30 mg per kg CyA, or vehicle 2 h before and 4,
24, and 48 h after exposure to the hapten. On day 5, six draining lymph
nodes were dissected and lymph node cell suspensions from each animal
were prepared as described in the previous section. The cells were
suspended in supplemented RPMI 1640 (4106 cells per ml) and placed
in triplicate in 100 ml medium into £at-bottomed wells (96-well plates).
For in vitro hapten pulse, 100 ml 0.5 mM aqueous solution of 2,4-
dinitrobenzenesulfonic acid sodium salt (DNBS, a water-soluble analog of
DNFB, Sigma-Aldrich) were added to the cells (Nuriya et al, 2001). After
incubation in a humidi¢ed atmosphere at 371C for 3 d, hapten-speci¢c cell
proliferation was assessed with a colorimetric immunoassay (Roche
Diagnostics, Mannheim, Germany) using a 16 h 5-bromo-20 -deoxyuridine
incorporation. The assay was performed according to the manufacturer’s
instruction. For comparison cultures without hapten pulse were used.
Statistical analyses Individual data of test and control (vehicle-treated)
groups obtained from repeated studies were pooled and evaluated with
one-way analysis of variance followed by Dunnet’s post hoc test
(parametric test) or by Kruskal^Wallis and Dunn’s test (nonparametric)
using the SigmaStats program, version 2.3.
RESULTS
Pimecrolimus and tacrolimus equally inhibit the elicitation
phase of ACD; both are superior to CyA Contact
hypersensitivity reaction was dose-dependently and with
equivalent potency and e⁄cacy inhibited by oral treatment with
pimecrolimus and tacrolimus (Fig 1). Treatment with 2 90 mg
per kg resulted in an inhibition by 58%^63%. Doses of 2 30
mg per kg led to an inhibition by 40%, whereas doses of 210
mg per kg had e¡ects below the level of statistical signi¢cance.
CyA showed signi¢cant inhibition only at the highest dose
tested (2 90 mg per kg).
Pimecrolimus does not interfere with the sensitization phase
of ACD, in contrast to tacrolimus and CyA Contact
hypersensitivity response in passively sensitized mice was not
inhibited when the transferred lymph node cells were collected
from mice treated orally with pimecrolimus during the
sensitization phase (Fig 2). Even four doses of 120 mg per kg
pimecrolimus (i.e.,48-fold the minimal total dose needed to
inhibit the elicitation phase), given 2 h before and 4, 24, and
48 h after the hapten exposure did not result in statistically
signi¢cantly di¡erent hypersensitivity responses compared to
vehicle-treated mice. In contrast, treatment with tacrolimus at
430 mg per kg (i.e., 2-fold the minimal total dose inhibiting
the elicitation phase) resulted in an inhibition by 72%. A similar
e¡ect was observed with CyA at 60 mg per kg (1.3-fold the
minimal total dose needed to inhibit the elicitation phase). The
impairment of the sensitization phase by tacrolimus and CyA
was dose-dependent.
The interference of tacrolimus and CyAwith the sensitization
phase was associated with an inhibition of the hyperplasia of the
draining lymph nodes (Table I). Hyperplasia was inhibited by
44% (weight) and 40% (cellularity) with tacrolimus at 430
mg per kg and by 53% (weight) and 54% (cellularity) with 60
mg per kg CyA. No e¡ect on lymph node hyperplasia was
observed in pimecrolimus-treated mice even up to the highest
dose tested (4120 mg per kg).
As inhibition of lymph node hyperplasia indicated a sup-
pression of antigen-speci¢c lymphocyte proliferation, additional
studies on hapten-speci¢c T cell proliferation with DNFB and its
water-soluble analog DNBS were performed ex vivo.
Inhibition of the sensitization phase of ACD by tacrolimus is
associated with impaired proliferation of antigen-speci¢c
lymph node cells in vitro Cultured lymph node cells from
DNFB-sensitized and vehicle-treated mice exhibited a 9-or 13-
fold increased proliferative response after a pulse with DNBS
compared to cells from naive mice (Table II). The antigen-
speci¢c proliferative response was not inhibited in lymph node
cells collected from mice treated with pimecrolimus at the
highest dosage tested (four doses of 90 mg per kg). In contrast,
response to the hapten pulse was signi¢cantly inhibited by 37%
in lymph node cell cultures prepared from DNFB-sensitized
mice treated with 10 mg per kg tacrolimus or by 65% in cells
from mice treated with 30 mg per kg CyA.
DISCUSSION
The side by side comparison of pimecrolimus, tacrolimus, and
CyA in mice showed that the two phases of ACD are di¡erently
a¡ected by the compounds although inhibition of calcineurin
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Figure1. Pimecrolimus and tacrolimus inhibit the elicitation phase
of ACD equally and more e⁄caciously than CyA. Treatment-related
inhibition of the elicitation phase was determined in actively sensitized
mice by assessment of di¡erences in auricular weights in drug- and vehi-
cle-treated animals. Treatment was performed 2 h before and 4 h after chal-
lenge: n.s., not signi¢cantly di¡erent (p40.05) from vehicle-treated
animals (controls); nnnpo0.001 vs controls (di¡erences in auricular weights
in controls 24 h after challenge: 27.574.7 mg).
Figure 2. Pimecrolimus does not interfere with the sensitization
phase of ACD in contrast to tacrolimus and CyA. Inhibition of the
sensitization phase was assessed by the hypersensitivity response at chal-
lenged ears (di¡erences in auricular weight) of mice passively sensitized
with transferred lymph node cells from donors treated 2 h before and 4,
24, and 48 h after sensitization; n.s., not signi¢cantly di¡erent (p40.05)
from vehicle-treated animals (controls); nnnpo0.001 vs controls (di¡erences
in auricular weights in controls 24 h after challenge: 19.573.2 mg).
Table I. E¡ects of treatment with pimecrolimus, tacrolimus, or CyA during the induction phase of ACD on weight and
cellularity (in italics) of draining lymph nodes
% Inhibition of lymph node hyperplasia (weight), % Reduction in cellularity (mean7SEM (number of animals))
Treatment (4  mg per kg oral) Pimecrolimus Tacrolimus CyA
120 673.5 n.s. (20) ^ ^
1376.7 n.s. (12)
90 1072.5 n.s. (27) ^ ^
876.8 n.s. (12) ^ ^
60 ^ ^ 5371.7nnn (31)
^ ^ 5475.7nnn (16)
30 372.0 n.s. (27) 4471.6nnn (27) 973.2nn (10)
^875.4 n.s. (12) 4073.7nnn (12) 1775.2nn (8)
10 ^ 1772.1nnn (27) ^
676.4n.s. (12) ^
^, not tested; n.s., not signi¢cantly di¡erent (p40.05) from vehicle-treated animals (controls).
nnpo0.01, nnnpo0.001 vs controls.
Table II. Antigen-speci¢c proliferative response of lymph node cells from DNFB-sensitized mice with/without pimecrolimus,
tacrolimus, or CyA treatment
Treatment group Proliferative response, mean7SD, OD 450 (number of animals) % Inhibition, mean7SEM
PimecrolimusI 0.6070.15 8711.1% n.s.
4  90 mg per kg, oral (8)
TacrolimusI 0.4170.10 3777.5%nnn
4  10 mg per kg, oral (8)
CyAII 0.1670.12 6574.7nnn
4  30 mg per kg, oral (8)
Vehicle I-treated sensitized controls 0.6570.26 ^
(8)
Vehicle II-treated sensitized controls 0.4670.23 ^
(8)
Non-sensitized controls 0.0570.03 ^
(16)
^, not tested; n.s. not statistically signi¢cantly di¡erent (p40.05) from DNFB-sensitized and vehicle-treated animals (controls); I, II, corresponding vehicle.
nnnpo0.001 vs controls.
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activity and thereby thus inhibition of gene transcription is the
common molecular mechanism of action. Pimecrolimus and ta-
crolimus inhibited the in£ammatory response of the elicitation
phase with similar potencies and e⁄cacies and were superior in
activities to CyAwhen equal doses, expressed as mg per kg, were
used. In comparison with oral doses used in patients with psoria-
sis (Ho et al, 1999; Anonymous, 1996; Rappersberger et al, 2002)
the minimal e¡ective doses in mice are high. It has to be consid-
ered, however, that the murine dose equivalent factor of these
compounds is higher than the commonly calculated factor of
12.5 (Van Mierth, 1989) and that therapeutic approaches and treat-
ment schedules are di¡erent. On a molar basis, CyA (MW 1202)
was under-dosed by approximately one-third in relation to pime-
crolimus and tacrolimus, which were tested in almost equimolar
amounts (MW 811 and MW 822, respectively). The same doses
a¡ecting the elicitation phase had been used to study the in£u-
ence of the compounds on the induction phase with the di¡er-
ence that the animals were treated with four doses distributed
over three consecutive days to ensure drug exposure during the
sensitization period. Doses of 30 or 90 mg per kg pimecrolimus,
which inhibited the elicitation phase equally to tacrolimus and
better than CyA (Fig 1), did not interfere with the sensitization
phase. Even doses of 120 mg per kg pimecrolimus had no statis-
tically signi¢cant e¡ects (Fig 2). In contrast, treatment with ta-
crolimus at 30 mg per kg or CyA at 60 mg per kg resulted in a
pronounced inhibition of sensitization. This e¡ect was associated
with an inhibition of the hyperplasia of the draining lymph
nodes in the treated animals (Table I). Therefore, twice as many
tacrolimus- and CyA-treated cell donors than pimecrolimus-trea-
ted donors were needed for the transfer studies. A comparison at
the 90 mg per kg level was impossible because the lymph nodes
of tacrolimus-treated animals were highly atrophic and animals
treated with 4 90 mg per kg CyA died or had to be killed due
to severe toxic signs ahead of schedule. As expected, inhibition of
sensitization was accompanied by impaired proliferation of anti-
gen-speci¢c lymph node cells ex vivo (Table II). This assay proved
to be very sensitive as the compounds inhibited hapten-speci¢cT
cell proliferation at doses that only marginally a¡ected lymph
node weight and cellularity and did not signi¢cantly inhibit
the in£ammatory ear response in passively sensitized mice.
The di¡erential e¡ects of pimecrolimus, tacrolimus, and CyA
on the sensitization phase in vivo are surprising and need further
studies to elucidate these pharmacodynamic di¡erences. In fact,
previous studies showed that CyA is more than 10-fold less potent
than pimecrolimus and tacrolimus at theTcell level in vitro (Tocci
et al, 1989; Grassberger et al, 1999; Kaltho¡ et al, 2002). Further-
more, a recent side by side comparison of pimecrolimus and ta-
crolimus addressing the inhibition of the stimulated expression of
interleukin-2 (IL-2), IL-3, IL-8, granulocyte-macrophage colony-
stimulating factor, and tumor necrosis factor a in the human T
cell line Jurkat showed that pimecrolimus was nearly as potent
as tacrolimus at both the mRNA level and the protein level.2
Although this appears to be in con£ict with our ¢ndings, it may
be explained by a distinct distribution and bioavailability of the
active drugs in skin, subcutaneous lymphoid compartment, and
draining lymph nodes. Indeed, the tissue distribution of the two
compounds di¡ered in rats treated orally with pimecrolimus or
tacrolimus.3 The concentration of pimecrolimus in skin was
higher than that of tacrolimus but the concentration in lymph
nodes was lower. As another possibility, the compounds may dif-
ferentially a¡ect antigen-presenting cells or T cells as the relevant
immunologic targets in the cascade from the ¢rst hapten contact in
the skin to the priming of antigen-reactive T cells in the draining
lymph nodes. In this context, it is interesting that human Langer-
hans cells exposed ex vivo to 10^8 mol per liter tacrolimus showed
reduced expression of major histocompatibility complex class I and
II antigens and costimulatory molecules, such as CD40 and CD80,
and exhibited a severely reduced Tcell stimulatory ability in a skin
mixed lymphocyte reaction (Panhans-Gross et al, 2001).
These data demonstrate that pimecrolimus has a more speci¢c
pharmacologic pro¢le than CyA and tacrolimus, indicating that
pimecrolimus might have a lower potential for side-e¡ects. This,
however, has to be con¢rmed by a head to head comparison in
clinical studies.
REFERENCES
Anonymous Systemic tacrolimus (FK 506) is e¡ective for the treatment of psoriasis
in a double-blind, placebo-controlled study. The European FK 506 Multicen-
tre Psoriasis Study Group.. Arch Dermatol 132:419^423, 1996
Bornh˛vd E, Burgdorf WHC,Wollenberg A: Macrolactam immunomodulators for to-
pical treatment of in£ammatory skin diseases. JAm Acad Dermatol 45:736^743, 2001
Eichen¢eld LF, LuckyAW, Boguniewicz M, et al: Safety and e⁄cacy of pimecrolimus
(ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis
in children and adolescents. J Am Acad Dermatol 46:495^504, 2002
Grabbe S, Schwarz T: Immunoregulatory mechanisms involved in elicitation of al-
lergic contact hypersensitivity. ImmunolToday 19:37^44, 1998
Grabbe S, Steinert M, Mahnke K, et al: Dissection of antigenic and irritative e¡ects
of epicutaneously applied haptens in mice Evidence that not the antigen com-
ponent but nonspeci¢c proin£ammatory e¡ects of the haptens determine the
concentration-dependent elicitation of allergic contact dermatitis. J Clin Invest
98:1158^1164, 1996
Grassberger M, Baumruker T, Enz A, et al: A novel anti-in£ammatory drug, SDZ
ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br J Derma-
tol 141:264^273, 1999
Harper J, Green A, Scott G, et al: First experience of topical SDZ ASM 981 in chil-
dren with atopic dermatitis. Br J Dermatol 144:781^787, 2001
Ho VC, Gri⁄ths CE, Albrecht G, et al: Intermittent short courses of cyclosporin
(Neoral (R)) for psoriasis unresponsive to topical therapy: A 1-year multicentre,
randomized study. ThePISCES Study Group. Br J Dermatol 141:283^291, 1999
Kaltho¡ FS, Chung J, Stuetz A: Pimecrolimus inhibits up-regulation of OX40 and
synthesis of in£ammatory cytokines upon secondaryT cell activation by allo-
geneic dendritic cells. Clin Exp Immunol 130:1, 85^92, 2002
Kapp A, Papp K, Bingham A, et al: Long-term management of atopic dermatitis in
infants with topical pimecrolimus, a nonsteroid anti-in£ammatory drug. J Al-
lergy Clin Immunol 110:277^284, 2002
Koo J: Cyclosporine in dermatology ^ fears and opportunities. Arch Dermatol 131:842^
845, 1995
Luger T,Van Leent EJ, Graeber M, et al: SDZ ASM 981. An emerging safe and e¡ec-
tive treatment for atopic dermatitis. Br J Dermatol 144:788^974, 2001
Meingassner JG, Grassberger M, Fahrngruber H, et al: A novel anti-in£ammatory
drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo
pharmacology. Br J Dermatol 137:568^576, 1997
Nuriya S, Enomoto S, Azuma M:The role of CTLA-4 in murine contact hypersen-
sitivity. J Invest Dermatol 116:764^768, 2001
Panhans-Gross A, Novak N, Kraft S, Bieber T: Human epidermal Langerhans cells
are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy
Clin Immunol 107:345^352, 2001
Rappersberger K, Komar M, Ebelin ME, et al: Pimecrolimus identi¢es a common
genomic anti-in£ammatory pro¢le, is clinically highly e¡ective in psoriasis
and is well tolerated. J Invest Dermatol 119:876^887, 2002
RuzickaT, Assmann T, Homey B: Tacrolimus ^ the drug for the turn of the millen-
nium. Arch Dermatol 135:574^580, 1999
Salerno A, Bonanno CT, Caccamo N, et al: The e¡ect of cyclosporin A, FK506 and
rapamycin on the murine contact sensitivity reaction. Clin Exp Immunol
112:112^119, 1998
Tocci MJ, Matkovich DA, Collier KA, et al: The immunosuppressant FK506 selec-
tively inhibits expression of early T cell activation genes. J Immunol 143:718^
726, 1989
Tsuji RF, Kawikova I, Ramabhadran R, et al: Early local generation of C5a initiates
the elicitation of contact sensitivity by leading to early T cell recruitment.
J Immunol 165:1588^1598, 2000
Van Leent EJM, Ebelin ME, Burtin P, et al: Low systemic exposure after repeated
topical application of pimecrolimus (Elidels, SDZ ASM 981) in patients with
atopic dermatitis. Dermatology 204:63^68, 2002
Van Mierth AS: Extrapolation of pharmacological and toxicological data based on
metabolic weight. Arch ExpVeterinarmed 43:481^488, 1989
Wahn U, Bos JD, Good¢eld M, et al: E⁄cacy and safety of pimecrolimus cream in
the long-term management of atopic dermatitis in children. Pediatrics 110
(1 Part 1): e2, 2002
2Winiski A,Wang S, Schwendinger B, Stuetz A: Inhibitory activity of
pimecrolimus and tacrolimus on induced cytokine mRNA and protein ex-
pression in a humanTcell line (Jurkat) measured via RT-PCR and ELISA.
J Invest Dermatol 119:347, 2002 (Abstr.)
3Meingassner JG, Hiestand P, Bigout M, et al: SDZ ASM 981 is highly
e¡ective in animal models of skin in£ammation, but has only low activity
in models indicating immunosuppressive potential, in contrast to cyclos-
porine A and FK 506. J Invest Dermatol 117:532, 2001 (Abstr.)
80 MEINGASSNER ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
